June 25, 2024
Those Lilly letters
We learned this week that several compounding pharmacies have received a cease-and-desist letter from a law firm representing Eli Lilly.
June 16, 2024
When media does its job
Well check this out: A news story about compounded GLP-1s that’s actually accurate, sans all the usual hand-wringing and fear-mongering.
June 16, 2024
The cover of the Rolling Stone?
Okay, not quite the cover, but APC has certainly been quoted in that and dozens of other publications over the past several months as the GLP-1 phenomenon has shone a bright light on pharmacy compounding.
June 16, 2024
GLP-1 misinfo affects you — here’s what to do about it
Learn what’s at stake and what APC is doing about it — and how you can help … even if you don’t compound GLP-1s.
June 16, 2024
FDA listened, we spoke
The FDA held a listening session on the "Use and Processes of Advisory Committees" on Thursday. APC's Tenille Davis and PCCA's AJ Day were there.
June 7, 2024
How does this protect patients?
In comments submitted earlier this week, APC took issue with provisions of proposed new compounding regulations from the California Board of Pharmacy.
June 7, 2024
Tampa with us: It’s next Wednesday
APC will be in Tampa next Wednesday, June 12 for a CompoundED UpDATE regional meeting, made possible by a grant from PCCA. Also, Topi-CLICK is sponsoring an APC ‘Compounder Get-Together” in Boston on the evening of June 18.
June 7, 2024
Ketamine? GLP-1s? We’ve got tips for you
We’re less than six weeks from EduCon 2024, APC’s hot-topics-and-best-practice webinar series for compounding pharmacists and technicians.
June 7, 2024
We need to talk.
Why? Because the current misinformation about compounding – particularly compounded GLP-1s – is a hairball that the media can’t seem to cough up.
June 6, 2024
Compounded sublingual semaglutide: It isn’t a copy
APC has created a one-pager explanation for you to share.
